| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.37 | 0.02 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |